Abstract:ObjectiveTo investigate the clinical effect of 24-week tenofovir disoproxil fumarate (TDF) sequential therapy in HBeAg-positive chronic hepatitis B (CHB) patients with suboptimal serological response to 48-week pegylated interferon-α-2a (Peg-IFN-α-2a) monotherapy. MethodsA total of 21 patients who did not achieve HBeAg seroconversion after the 48-week Peg-IFN-α-2a monotherapy at a dose of 180 μg/week were enrolled. Among these patients, 11 were given TDF 300 mg/d in addition, the withdrawal of Peg-IFN-α-2a after 12 weeks, and TDF monotherapy for 12 weeks; 10 were given sequential adefovir dipivoxil (ADV) monotherapy at a dose of 10 mg/d for 24 weeks. The indicators including HBV DNA, liver and renal function, and HBV serological markers were measured at weeks 12 and 24 of treatment, and the clinical outcome was compared between the two groups. The independent samples t-test was used for comparison of normally distributed continuous data between groups and the paired t-test was used for comparison of normally distributed continuous data within one group; the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between groups. The Fisher's exact test was used for comparison of categorical data. ResultsAt weeks 12 and 24 of treatment, there were no significant differences in HBsAg and HBeAg levels between groups (both P＞0.05). At week 24 of treatment, there was no significant difference in HBeAg seroconversion rate between the TDF group and the ADV group ［18.2% (2/11) vs 10.0% (1/10), P＞0.05］. At weeks 12 and 24 of treatment, the TDF group had significant reductions in HBeAg compared with baseline (1.75±0.59 log10S/CO、1.61±0.70 log10S/CO vs 1.86±0.58 log10S/CO, P=0.017 and 0.027). At week 24 of treatment, the TDF group had a significantly lower alanine aminotransferase (ALT) level than the ADV group ［21.0 (15.0-27.0) U/L vs 33.0 (21.5-63.5) U/L, P=0.046］. There were no significant differences in estimated glomerular filtration rate at weeks 12 and 24 of treatment between the two groups (both P＞0.05). ConclusionAs for CHB patients with suboptimal serological response to 48-week Peg-IFN-α-2a monotherapy, addition of TDF for 12 weeks and then TDF monotherapy for 12 weeks helps to achieve greater reductions in serum ALT and HBeAg levels compared with sequential ADV therapy.

Clinical Effect of Xiaoyao Pill Auxiliary Adefovir Dipivoxil on Patients with Chronic Hepatitis B

[The Analyse of Effectiveness in HBeAg-positive Chronic Viral Hepatitis B Treated by Adefovir Dipivoxil Combined with Bicyclol].

The Clinical Efficacy of the Adefovir Dipivoxii in the Treatment of 36 Chronic Hepatitis B Patients with HBeAg-positive

Efficacy of different therapeutic modalities for patients with acute-on-chronic liver failure induced by hepatitis B

Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial.

Efficacy of adefovir dipivoxil in treatment of chronic hepatitis B patients with lamivudine resistance

Clinical Trail of Decoction of Tonifying Qi Activating Blood and Detoxifcation in the Treatment of Chronic Hepatitis B Patients with Alanine Aminotransferase Less than Two-time upper Limits of Normal Level

Adefovir Dipivoxil Plus Chinese Medicine in HBeAg-Positive Chronic Hepatitis B Patients: A Randomized Controlled 48-Week Trial

A Double-Blind Randomized Trial of Adefovir Dipivoxil in Chinese Subjects with HBeAg-positive Chronic Hepatitis B

Hepatic histological changes after 48 weeks adefovir dipivoxil treatment in patients with HBeAg- positive chronic hepatitis B

Clinical and Experimental Effectiveness of Astragali Compound in the Treatment of Chronic Viral Hepatitis B

A Randomized, Multi-Central, Controlled Study of Patients with Hepatitis B E Antigen-Positive Chronic Hepatitis B Treated by Adefovir Dipivoxil or Adefovir Dipivoxil Plus Bicyclol

Tenofovir disoproxil fumaratevs adefovir dipivoxil in Chinese treatment naive patients with chronic hepatitis B for 48 weeks：a randomized, double-blinded, controlled study

Five years of treatment with adefovir dipivoxil in Chinese patients with HBeAg-positive chronic hepatitis B.

Efficacy of Combined Therapy in Patients with Hepatitis B Virus-Related Decompensated Cirrhosis.

The clinical analysis of PEG-interferon alpha-2b therapy in 61 cases of HBeAg-positive chronic hepatitis B

A Randomized, Double-Blind, Multicenter Study of Adefovir Dipivoxil in Treating Patients with HBeAg-positive Chronic Hepatitis B

Effect of Telbivudine Therapy on the Cellular Immune Response in Chronic Hepatitis B

Systematic evalution of Fuzheng Huayu Capsule combined with Adefovir Dipivoxil in treatment of chronic hepatitis B with hepatic fibrosis

Clinical effect of 24-week TDF versus ADV sequential therapy in HBeAg-positive chronic hepatitis B patients with suboptimal response to 48-week pegylated interferon-α-2a treatment

Factors associated with the therapeutic effect of lamivudine-resistant chronic hepatitis B during adefovir dipivoxil therapy